SAN DIEGO--(BUSINESS WIRE)--June 8, 2006--Phenomix Corporation, a drug discovery and development company, announced today the initiation of a Phase II clinical trial of PHX1149, a novel orally administered inhibitor of DPP4 for the treatment of type 2 diabetes. Phenomix’ clinical trial is a double-blind, randomized, placebo-controlled study in patients with type 2 diabetes. ADVERTISEMENT click here
